RO 5545965Alternative Names: RO-554965; RO5545965
Latest Information Update: 16 Jul 2016
At a glance
- Originator Roche
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Schizophrenia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in Netherlands (PO, Capsule)
- 01 Jun 2016 Roche initiates a phase I trial for Schizophrenia in USA (PO, Capsule) (NCT02824055)
- 01 Aug 2014 Roche completes a phase I trial in Schizophrenia in USA (NCT02019329)